NEW YORK, May 22 - Syrrx said today that it had appointed David Weitz as general counsel and vice president of intellectual property.
Weitz will develop, maintain, and defend the company's IP as it moves toward preclinical drug development.
Weitz was previously partner at the Palo Alto, Calif., law firm Wilson Sonsini Goodrich and Rosati, where he co-led patent prosecution.
Syrrx, based in San Diego, Calif., is a structural genomics company planning to move into drug development.
GPC Biotech has revamped its R&D management and hired on four new executives to its clinical development team, the company said on May 21.
Former Senior Vice President of Research Sebastian Meier-Ewert has been appointed both chief scientific officer of the company at large and chief operating officer of the firm's Waltham site. Meier-Ewert will move from Munich to Waltham. The previous chief operating officer for that facility, Muz Mansuri, resigned to become involved in venture capital, but will remain affiliated with the company as a consultant.
GPC also said that it has hired four executives to its Princeton, NJ clinical development group: Thomas McKearn, Edward McNiff, Michael Petrone, and John Slayback. Three of the four have been hired away from New Jersey neighbor Bristol-Myers Squibb.
McKearn, previously executive director of strategic science and medicine at Bristol-Myers Squibb's Pharmaceutical Research Institute, has taken the role of vice president for medical affairs. He will oversee clinical-study protocols, interact with regulatory agencies and be involved in in-licensing.
McKniff, vice president of pharmaceutical development, will design the company's pharmaceutical development strategy for new lead compounds. He was previously vice president for analytical research and development at Bristol Myers Squibb's Pharmaceutical Research Institute.
In July, Michael Petrone will join GPC as vice president of clinical operations from Genaera Corporation, where he is vice president for clinical research and regulatory affairs. Petrone will oversee project planning and clinical outsourcing.
Slayback, previously director of analytical R&D, late development and outsourcing at Bristol-Myers Squibb, has been hired at GPC as director of analytical formulation development and outsourcing.
GPC is based in Munich.
Bruce MacMillan has been hired as Caliper Technologies' vice president and general counsel, the company said on May 20.
MacMillan will serve as secretary to the board of directors, and oversee the company's legal affairs, intellectual property and collaborative contracts.
MacMillan was previously vice president, general counsel and corporate secretary for Sugen, which was acquired by Pharmacia.
Caliper Technologies is based in Mountain View, Calif.
Agencourt said on May 20 that it had added two senior members to its sales team.
Mann Shoffner, previously director of business development at MolecularWare, will be senior manager for marketing and business development. Prior to his most recent position, Shoffner was international sales manager for Packard, now PerkinElmer.
Kerri Anne Stellato will be the company's senior sales associate for the Midwest region, marketing genomic services and the company's Solid Phase Reversible Immobilization technology. She was previously at Integrated Genomics.
Simon Fraser University's Mike Volker will be a director at Genops Bioinformatics, the company said on May 17.
Volker is director of the University Industry Liaison Office at Simon Fraser, which is located in British Columbia. He is involved in a range of startups.
Genops is a two-year-old bioinformatics company headquartered in Burnaby, British Columbia.
Drug development service company PPD said on May 15 that chief financial officer Phillippe Maitre had resigned, and vice president of finance Linda Baddour would take on the role as his successor.
Baddour, 43, joined PPD in 1995. She was promoted to chief accounting officer in 1997 and to vice president of finance in 1998.
Maitre was appointed chief financial officer in August 2000.
PPD is based in Wilmington, NC.
Timothy Leach has joined Genome Therapeutics as vice president of clinical and medical affairs, the company said on May 9.
Leach will help the company develop a pharmaceutical portfolio, and guide the company's lead clinical candidate through phase III trials.
Leach was most recently medical director of Cubist Pharmaceuticals, and was previously at Pharmacia, as associate medical director for anti-bacterial clinical development.
Genome Therapeutics, based in Waltham, Mass., offers genomic services for pharmaceutical companies and works on its own drug development.
Nanogen said on May 8 that it had hired David Macdonald as senior vice president of operations.
Macdonald will lead product development, manufacturing and operations, and guide the company in its diagnostic product launches.
He was most recently president and CEO of both Progeny Systems and Medical Electronic Systems, and was previously president and COO of a division of Quest Diagnostics.